Analyst Price Targets — WGS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 12:45 pm | Mark Massaro | BTIG | $170.00 | $87.08 | TheFly | GeneDx price target lowered to $170 from $200 at BTIG |
| February 24, 2026 11:41 am | David Westenberg | Piper Sandler | $130.00 | $87.08 | TheFly | GeneDx price target lowered to $130 from $160 at Piper Sandler |
| February 23, 2026 8:49 pm | — | Jefferies | $150.00 | $87.08 | TheFly | GeneDx price target lowered to $150 from $180 at Jefferies |
| December 22, 2025 12:03 pm | — | Canaccord Genuity | $170.00 | $140.44 | TheFly | GeneDx price target raised to $170 from $160 at Canaccord |
| December 15, 2025 11:26 am | — | Wells Fargo | $155.00 | $151.37 | TheFly | GeneDx price target raised to $155 from $140 at Wells Fargo |
| December 12, 2025 12:26 pm | — | BTIG | $200.00 | $155.36 | TheFly | GeneDx price target raised to $200, named 2026 Top Pick at BTIG |
| October 29, 2025 11:22 am | — | BTIG | $165.00 | $137.40 | TheFly | GeneDx price target raised to $165 from $140 at BTIG |
| October 29, 2025 10:59 am | — | Canaccord Genuity | $160.00 | $137.47 | TheFly | GeneDx price target raised to $160 from $155 at Canaccord |
| October 29, 2025 10:47 am | — | Guggenheim | $170.00 | $137.47 | TheFly | GeneDx price target raised to $170 from $115 at Guggenheim |
| October 20, 2025 9:37 am | — | Canaccord Genuity | $155.00 | $120.94 | TheFly | GeneDx initiated with a Buy at Canaccord |
Latest News for WGS
COO Bryan Dechairo sold 5,961 directly-held shares for a transaction value of approximately $510,900 on Feb. 4, 2026. The sale represented 100% of Mr.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of GeneDx Holdings Corp. (NASDAQ: WGS) breached their fiduciary duties to shareholders.
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) announced that company management will participate in the upcoming TD Cowen and Barclays healthcare investor conferences.
GeneDx Holdings Corp (NASDAQ: WGS) reported better-than-expected fourth-quarter financial results on Monday.
GeneDx (WGS) is upgraded to 'Buy' as valuation resets and operational improvements support a more realistic growth outlook. Per my DCF model, WGS now targets 25% CAGR and 10% free cash flow margins, with potential to reach 14% FCF margin, making its valuation less stretched. Management plans to nearly triple its commercial footprint in 2026, prioritizing growth capture over near-term margins and signaling a ramp…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for WGS.
U.S. House Trading
No House trades found for WGS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.